Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 13, 2020, by Ultragenyx Pharmaceutical Inc. The filing primarily serves to disclose preliminary unaudited fiscal year 2019 financial highlights, 2020 revenue guidance for the product Crysvita, and significant regulatory developments. The Company expects to report full-year 2019 results in February 2020.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing preliminary unaudited fiscal year 2019 revenue, cash, and investments. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced exhibit and are not explicitly stated in the body of this report.
Material Changes and Regulatory Updates
- Regulatory Submission: On January 13, 2020, Ultragenyx and Kyowa Kirin Co., Ltd. submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA for Crysvita (burosumab).
- Indication Expansion: The sBLA seeks approval for the treatment of FGF23-related hypophosphatemia associated with phosphaturic mesenchymal tumors (tumor-induced osteomalacia; TIO) that cannot be curatively resected or localized.
- Investor Presentation: The Company posted a presentation to its website for the 38th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2020.
Guidance, Outlook, and Risks
The Company issued 2020 revenue guidance specifically for Crysvita in its territories, as detailed in the press release furnished as Exhibit 99.1. The filing notes that the information regarding financial results and the presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Key Facts for Investor Verification
- Verify the specific preliminary 2019 revenue and cash position figures in the press release (Exhibit 99.1), as they are not listed in this 8-K text.
- Confirm the details of the 2020 Crysvita revenue guidance provided in the press release.
- Monitor the status of the supplemental Biologics License Application (sBLA) for Crysvita regarding tumor-induced osteomalacia (TIO).
- Review the full presentation materials posted on the Company's investor website for additional strategic context.